To The Moon

$AbbVie(ABBV)$ is a leading global biopharmaceutical company based in the United States. Ranked among the largest in the industry, it develops treatments across key areas including immunology, cancer, neurology, and aesthetics. Its major products include blockbuster medicines like Humira, Skyrizi, and Rinvoq for autoimmune conditions, cancer therapies like Imbruvica and Venclexta, mental health medication Vraylar, and Botox.

The name "AbbVie" originates from a combination of "Abbott," the name of its former parent company, and "vie," which refers to a Latin root meaning 'life.'

1. In a long-term uptrend, but it is currently hitting a strong price ceiling at $260–$262. Momentum is slowing down, which suggests sellers are stepping in and could cause a short-term pullback.

2. Good news from cancer trial data and drug approvals keeps the stock supported.

IF THE PRICE BREAKS ABOVE $260

• Strategy: Buy an In-the-Money (ITM) or At-the-Money (ATM) Long Call

• Execution: Look at the $260 Call or the $270 Call on 3-4 months expiry.

• Logic: A sustained close above the $260–$261 overhead resistance confirms an upward breakout from the multi-month ascending channel. Choosing the 3-4 months contract cushions against short-term chop

IF THE PRICE REMAINS BELOW $260

• Strategy: Sell an Out-of-the-Money (OTM) Cash-Secured Put

• Execution: Look at the $240 Put on 1-month expiry.

• Logic: If ABBV fails to clear $260 and pulls back toward mid-channel support near $240, you collect premium upfront. If assigned at expiration, your net purchase cost drops below $240 ($240 strike minus $premium received).

EDUCATIONAL DISCLAIMER

This post is for educational and informational purposes only and does not constitute financial advice. Options involve significant risk and are not suitable for all investors. Always conduct your own research and assess your personal risk tolerance before trading.